Attovia Therapeutics (NASDAQ:ATTO) Director Colin Walsh Purchases 500,000 Shares of Stock

Posted by James Conley on Aug 13th, 2026

Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) Director Colin Walsh purchased 500,000 shares of the stock in a transaction dated Thursday, August 6th. The stock was purchased at an average cost of $17.00 per share, for a total transaction of $8,500,000.00. Following the completion of the purchase, the director directly owned 3,020,632 shares of the company’s stock, valued at approximately $51,350,744. The trade was a 19.84% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Colin Walsh also recently made the following trade(s):

On Wednesday, August 5th, Colin Walsh sold 105,807 shares of Attovia Therapeutics stock. The stock was sold at an average price of $21.28, for a total value of $2,251,572.96.

Attovia Therapeutics Price Performance

Shares of ATTO traded up $1.12 during mid-day trading on Thursday, reaching $19.18. The stock had a trading volume of 406,507 shares, compared to its average volume of 1,169,091. Attovia Therapeutics, Inc. has a 52-week low of $16.15 and a 52-week high of $22.79.

Institutional Trading of Attovia Therapeutics

An institutional investor recently raised its stake in Attovia Therapeutics stock. BlackRock Inc. boosted its holdings in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 164,358 shares of the company’s stock after acquiring an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 at the end of the most recent quarter.

Attovia Therapeutics Company Profile

(Get Free Report)

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.